Congress Needs To Review “Authorized” Generics, Hatch And Waxman Agree

The legislature should consider how “authorized” generics affect the incentive for generic companies to pursue patent challenges, Sen. Hatch (R-Utah) tells a Drug & Device Dialogue audio conference. Rep. Waxman (D-Calif.) says Congress must “revisit” Waxman/Hatch if CMS does not address authorized generics through Medicaid “best price” reporting.